Dosing adjustments in postpartum patients maintained on buprenorphine or methadone

Area of Science:

• Addiction Medicine
• Reproductive Psychiatry
• Pharmacology

Background:

• Limited research exists on agonist medication dose adjustments during the postpartum period.
• Opioid use disorder treatment during pregnancy often involves buprenorphine or methadone maintenance.
• Postpartum care requires careful consideration of medication stability and patient needs.

Purpose of the Study:

• To assess the necessity of dose adjustments for buprenorphine or methadone in the postpartum phase.
• To evaluate methadone dose changes in patients switching from buprenorphine postpartum.

Main Methods:

• A randomized, double-blind study comparing buprenorphine and methadone.
• Participants (N=18) received stable doses 3 weeks pre-delivery and 4 weeks postpartum.
• A subgroup switched from buprenorphine to methadone at 5 weeks postpartum for evaluation.

Main Results:

• No significant differences in dose adequacy, liking, or craving were found between buprenorphine and methadone groups pre- and post-delivery.
• Buprenorphine-maintained patients only required dose adjustments after transferring to methadone postpartum.
• Individual responses to medication conversion varied.

Conclusions:

• Stable buprenorphine or methadone doses are generally adequate postpartum.
• Close monitoring for signs of overmedication is crucial for all postpartum patients on agonist therapy.
• Medication switching postpartum may necessitate individualized dose adjustments and monitoring.